A Phase Ib Open-label Dose Escalation Study of MEK162 and RAF265 in Adult Patients With Advanced Solid Tumors Harboring RAS or BRAFV600E Mutations.
Phase of Trial: Phase I
Latest Information Update: 17 Feb 2016
At a glance
- Drugs Binimetinib (Primary) ; RAF 265 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Array BioPharma; Novartis
- 01 Sep 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 30 Aug 2013 Planned end date changed from 1 Aug 2013 to 1 Sep 2013 as reported by ClinicalTrials.gov.
- 27 Aug 2013 Planned end date changed from 1 Jul 2013 to 1 Aug 2013 as reported by ClinicalTrials.gov.